Malta - English - Medicines Authority

arrow generics limited whiddon valley barnstaple, north devon, ex32 8ns, united kingdom - alendronic acid - tablet - alendronic acid 10 mg - drugs for treatment of bone diseases

Malta - English - Medicines Authority

actavis group ptc ehf revkjavikurvegi 76-78, 220 hafnarfjordur, iceland - alendronic acid - tablet - alendronic acid 70 mg - drugs for treatment of bone diseases

Ireland - English - HPRA (Health Products Regulatory Authority)

wpr healthcare limited - alendronic acid - tablet - 70 milligram(s) - bisphosphonates; alendronic acid - bisphosphonates, for the treatment of bone diseases - treatment of postmenopausal osteoporosis. alendronic acid reduces the risk of vertebral and hip fractures.

Ireland - English - HPRA (Health Products Regulatory Authority)

rowex ltd - alendronic acid - tablet - 70 milligram(s) - bisphosphonates; alendronic acid

Malta - English - Medicines Authority

arrow generics limited - alendronic acid 70 mg - tablet

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - alendronate sodium monohydrate, quantity: 81.24 mg (equivalent: alendronic acid, qty 70 mg) - tablet, uncoated - excipient ingredients: croscarmellose sodium; microcrystalline cellulose; lactose monohydrate; magnesium stearate - treatment of osteoporosis, including glucocorticoid induced osteoporosis. osteoporosis must be confirmed by the finding of low bone mass of at least two standard deviations below the gender specific mean for young adults or by the presence of history of osteoporotic fracture. paget's disease of bone.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - alendronate sodium monohydrate, quantity: 46.42 mg (equivalent: alendronic acid, qty 40 mg) - tablet, uncoated - excipient ingredients: croscarmellose sodium; microcrystalline cellulose; lactose monohydrate; magnesium stearate - treatment of osteoporosis, including glucocorticoid induced osteoporosis. osteoporosis must be confirmed by the finding of low bone mass of at least two standard deviations below the gender specific mean for young adults or by the presence of history of osteoporotic fracture. paget's disease of bone.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - alendronate sodium monohydrate, quantity: 11.1 mg (equivalent: alendronic acid, qty 10 mg) - tablet, uncoated - excipient ingredients: croscarmellose sodium; microcrystalline cellulose; lactose monohydrate; magnesium stearate - treatment of osteoporosis, including glucocorticoid induced osteoporosis. osteoporosis must be confirmed by the finding of low bone mass of at least two standard deviations below the gender specific mean for young adults or by the presence of history of osteoporotic fracture. paget's disease of bone.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - alendronate sodium, quantity: 91.37 mg (equivalent: alendronic acid, qty 70 mg) - tablet - excipient ingredients: povidone; croscarmellose sodium; lactose monohydrate; magnesium stearate; microcrystalline cellulose - fonat is indicated for the treatment of: osteoporosis, including glucocorticoid-induced osteoporosis. fonat is indicated for the prevention of glucocorticoid-induced osteoporosis in those patients on long term corticosteroid therapy (see clinical trials, glucorticoid-induced osteoporosis). prior to treatment, osteoporosis must be confirmed by: - the finding of low bone mass of at least 2 standard deviations below the mean for young adults (gender specific), or by: - the presence of osteoporotic fracture.

New Zealand - English - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - alendronate sodium monohydrate 81.2mg equivalent to alendronic acid 70 mg; colecalciferol 0.14mg;   - film coated tablet - active: alendronate sodium monohydrate 81.2mg equivalent to alendronic acid 70 mg colecalciferol 0.14mg   excipient: butylated hydroxytoluene colloidal silicon dioxide copovidone magnesium stearate mannitol medium-chain triglycerides microcrystalline cellulose   opadry white 85f18378 purified water sucrose - indicated for the treatment of osteoporosis in select patients where viatmin d supplementation is recommended.